EXCERPT
Slough, UK and Richmond, VA, May 9, 2019 – Indivior PLC (LON: INDV) (“Indivior” or the “Group”) today announced that it has entered into a definitive license agreement with HLS Therapeutics Inc. (TSX: HLS) (“HLS”) for exclusive commercialization rights to PERSERIS™ (risperidone) in Canada.
HLS is a specialty pharmaceutical company focused on acquiring and commercializing latestage products for the Canadian market. Commercially, if approved, PERSERISTM would be complementary to HLS’ product Clozaril® (clozapine), an atypical antipsychotic which, in Canada, is indicated for the management of the symptoms of treatment-resistant schizophrenia (“TRS”). HLS employs a unique branded platform called the Clozaril® Support and Assistance Network (“CSAN®”) that includes value-added treatment provider and patient services to support Clozaril®. PERSERIS, if approved, could benefit from the CSAN® offerings.
